Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus

The mTORC1 inhibitor everolimus (Afinitor/RAD001) has been approved for multiple cancer indications, including ER(+)/HER2(−) metastatic breast cancer. However, the combination of everolimus with the dual PI3K/mTOR inhibitor BEZ235 was shown to be more efficacious than either everolimus or BEZ235 alo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cold Spring Harb Mol Case Stud
Main Authors: Brannon, A. Rose, Frizziero, Melissa, Chen, David, Hummel, Jennifer, Gallo, Jorge, Riester, Markus, Patel, Parul, Cheung, Wing, Morrissey, Michael, Carbone, Carmine, Cottini, Silvia, Tortora, Giampaolo, Melisi, Davide
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory Press 2016
Assuntos:
Research Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4849849/
https://ncbi.nlm.nih.gov/pubmed/27148582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/mcs.a000620
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados